Benazepril

Jump to: navigation, search
Benazepril
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Brand Names
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2], Ahmed Zaghw, M.D. [3], Abdurahman Khalil, M.D. [4], Sheng Shi, M.D. [5], Jesus Rosario Hernandez, M.D. [6]

Synonyms / Brand Names: Lotensin®

Disclaimer

WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.

Black Box Warning

FETAL TOXICITY

See full prescribing information for complete boxed warning.

  • When pregnancy is detected, discontinue benazepril hydrochloride as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Overview

Benazepril is an angiotensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension. There is a Black Box Warning for this drug as shown here. Common adverse reactions include cough, dizziness, fatigue, and headache.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Hypertension
  • Dosing Information
  • Initial dose (not receiving a diuretic): Benazepril 10 mg PO qd
  • Initial dose (concurrent diuretic use): the diuretic should be discontinued 2 to 3 days prior to initiating Benazepril to reduce the likelihood of hypotension. If blood pressure is not controlled with Benazepril alone, diuretic should be resumed and Benazepril 5 mg PO qd should be used.
  • Maintenance dose:Benazepril 20—40 mg PO qd or Benazepril 10—20 mg PO bid (MAX 80 mg/day)
  • The divided regimen was more effective in controlling trough (pre-dosing) blood pressure than the same dose given as a once-daily regimen. Dosage adjustment should be based on measurement of peak (2-6 hours after dosing) and trough responses. If a once-daily regimen does not give adequate trough response, an increase in dosage or divided administration should be considered.
For Hypertensive Patients with Renal Impairment
  • Dosing Information
  • Dosage may be titrated upward until blood pressure is controlled or to a maximum total daily dose of 40 mg gs.[1]

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Heart Failure, Stage B
  • Recommendation
Myocardial Infarction
  • Recommendation

Non–Guideline-Supported Use

Diabetic Nephropathy
  • Dosing Information
Kidney Disease, Non-Diabetic
  • Dosing Information
Left Ventricular Hypertrophy
  • Dosing Information
  • Benazepril 20 mg PO qd for 2 weeks, followed by Benazepril 40 mg qd or combination of Benazepril 40 mg PO qd and amlodipine 5 mg PO qd[6]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Hypertension
  • Dosing Information
  • Initial dose: Benazepril 0.2 mg/kg PO qd (for pediatric patients above the age of 6 years)
  • For pediatric patients who cannot swallow tablets, or for whom the calculated dosage (mg/kg) does not correspond to the available tablet strengths for Benazepril, follow the suspension preparation instructions to administer Benazepril HCl as a suspension.
Hypertensive Patients with Renal Impairment
  • Dosing Information
  • Dosage may be titrated upward until blood pressure is controlled or to a maximum total daily dose of 40 mg.

Off-Label Use and Dosage (Pediatric)

There is limited information about Off-Label Use and Dosage of Benazepril tablet in pediatric patients.

Contraindications

Warnings

Anaphylactoid and Possibly Related Reactions
  • Head and Neck Angioedema
  • Angioedema of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors. In U.S. clinical trials, symptoms consistent with angioedema were seen in none of the subjects who received placebo and in about 0.5% of the subjects who received Benazepril. Angioedema associated with laryngeal edema can be fatal. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, treatment with Benazepril should be discontinued and appropriate therapy instituted immediately. Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine injection 1:1000 (0.3 mL to 0.5 mL) should be promptly administered.
  • Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks.
  • Intestinal Angioedema
  • Anaphylactoid Reactions During Desensitization
  • Anaphylactoid Reactions During Membrane Exposure
Hypotension
  • Benazepril can cause symptomatic hypotension. Like other ACE inhibitors, Benazepril has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume-and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Volume-and/or salt-depletion should be corrected before initiating therapy with Benazepril.
  • If hypotension occurs, the patient should be placed in a supine position, and, if necessary, treated with intravenous infusion of physiological saline. Benazepril treatment usually can be continued following restoration of blood pressure and volume.
Fetal toxicity
  • In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Benazepril, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Benazepril for hypotension, oliguria, and hyperkalemia.
  • No teratogenic effects of Benazepril were seen in studies of pregnant rats, mice, and rabbits. On a mg/m2 basis, the doses used in these studies were 60 times (in rats), 9 times (in mice), and more than 0.8 times (in rabbits) the maximum recommended human dose (assuming a 50-kg woman). On a mg/kg basis these multiples are 300 times (in rats), 90 times (in mice), and more than 3 times (in rabbits) the maximum recommended human dose.
Hepatic Failure

Adverse Reactions

Clinical Trials Experience

  • Benazepril has been evaluated for safety in over 6000 patients with hypertension; over 700 of these patients were treated for at least one year. The overall incidence of reported adverse events was comparable in Benazepril and placebo patients.
  • The reported side effects were generally mild and transient, and there was no relation between side effects and age, duration of therapy, or total dosage within the range of 2 to 80 mg. Discontinuation of therapy because of a side effect was required in approximately 5% of U.S. patients treated with Benazepril and in 3% of patients treated with placebo.
  • The most common reasons for discontinuation were headache (0.6%) and cough (0.5%)
  • The side effects considered possibly or probably related to study drug that occurred in U.S. placebo-controlled trials in more than 1% of patients treated with Benazepril are shown below.
Benazepril tablet adverse reactions.png
  • Other adverse experiences reported in controlled clinical trials (in less than 1% of Benazepril patients or with less than 1% difference in incidence between Benazepril or placebo treatment), and rarer events seen in post-marketing experience, include the following (in some, a causal relationship to drug use is uncertain):
  • Dermatologic
  • Gastrointestinal
  • Hematologic
  • Neurologic and Psychiatric
  • Other
  • Clinical Laboratory Test Findings
  • Hemoglobin
  • Decreases in hemoglobin (a low value and a decrease of 5 g/dL) were rare, occurring in only 1 of 2,014 patients receiving Benazepril alone and in 1 of 1,357 patients receiving Benazepril plus a diuretic. No U.S. patients discontinued treatment because of decreases in hemoglobin.
  • Other (causal relationships unknown)
  • Pediatric Patients
  • The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients.

Postmarketing Experience

  • FDA Package Insert for Benazepril contains no information regarding Postmarketing Experience.

Drug Interactions

Diuretics

  • Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Benazepril. The possibility of hypotensive effects with Benazepril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Benazepril. If this is not possible, the starting dose should be reduced.

Potassium supplements and potassium-sparing diuretics

  • Concomitant use with Benazepril may effect potassium levels. Monitor potassium periodically.

Oral anticoagulants

  • Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.

Lithium

Gold

Anti-diabetics

  • In rare cases, diabetic patients receiving an ACE inhibitor (including Benazepril) concomitantly with insulin or oral anti-diabetics may develop hypoglycemia. Such patients should therefore be advised about the possibility of hypoglycemic reactions and should be monitored accordingly.

NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) including selective COX-2 inhibitor|cyclooxygenase-2 inhibitors (COX-2 inhibitors)

Miscellaneous

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): D
Pregnancy Category (AUS): Benazepril is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.
  • Fetal toxicity
  • In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Benazepril, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Benazepril for hypotension, oliguria, and hyperkalemia.
  • No teratogenic effects of Benazepril were seen in studies of pregnant rats, mice, and rabbits. On a mg/m2 basis, the doses used in these studies were 60 times (in rats), 9 times (in mice), and more than 0.8 times (in rabbits) the maximum recommended human dose (assuming a 50-kg woman). On a mg/kg basis these multiples are 300 times (in rats), 90 times (in mice), and more than 3 times (in rabbits) the maximum recommended human dose.

Labor and Delivery

  • FDA Package Insert for Benazepril contains no information regarding Labor and Delivery.

Nursing Mothers

  • Minimal amounts of unchanged Benazepril and of benazeprilat are excreted into the breast milk of lactating women treated with Benazepril. A newborn child ingesting entirely breast milk would receive less than 0.1% of the mg/kg maternal dose of Benazepril and benazeprilat.

Pediatric Use

  • Neonates with a history of in utero exposure to Benazepril
  • If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Benazepril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means; there are occasional reports of benefit from these maneuvers with another ACE inhibitor, but experience is limited.
  • The antihypertensive effects of Benazepril have been evaluated in a double-blind study in pediatric patients 7 to 16 years of age . The pharmacokinetics of Benazepril have been evaluated in pediatric patients 6 to 16 years of age . Benazepril was generally well tolerated and adverse effects were similar to those described in adults.The long-term effects of Benazepril on growth and development have not been studied. Infants below the age of 1 year should not be given Benazepril because of the risk of effects on kidney development.
  • Treatment with Benazepril is not recommended in pediatric patients less than 6 years of age , and in children with glomerular filtration rate <30 mL/min as there are insufficient data available to support a dosing recommendation in these groups.

Geriatric Use

  • Of the total number of patients who received Benazepril in U.S. clinical studies of Benazepril, 18% were 65 or older while 2% were 75 or older. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
  • Benazepril and benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

FDA Package Insert for Benazepril contains no information regarding Gender.

Race

FDA Package Insert for Benazepril contains no information regarding Race.

Renal Impairment

Hepatic Impairment

Carcinogenesis, Mutagenesis, Impairment of Fertility

  • No evidence of carcinogenicity was found when Benazepril was administered to rats and mice for up to two years at doses of up to 150 mg/kg/day. When compared on the basis of body weights, this dose is 110 times the maximum recommended human dose. When compared on the basis of body surface areas, this dose is 18 and 9 times (rats and mice, respectively) the maximum recommended human dose (calculations assume a patient weight of 60 kg).
  • No mutagenic activity was detected in the Ames test in bacteria (with or without metabolic activation), in an in vitro test for forward mutations in cultured mammalian cells, or in a nucleus anomaly test.
  • In doses of 50-500 mg/kg/day (6-60 times the maximum recommended human dose based on mg/m2 comparison and 37-375 times the maximum recommended human dose based on a mg/kg comparison), Benazepril had no adverse effect on the reproductive performance of male and female rats.

Immunocompromised Patients

FDA Package Insert for Benazepril contains no information regarding Immunocompromised Patients.

Miscellaneous

Hyperkalemia

Cough

  • Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.

Surgery/Anesthesia

  • In patients undergoing surgery or during anesthesia with agents that produce hypotension, Benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. Hypotension that occurs as a result of this mechanism can be corrected by volume expansion.

Administration and Monitoring

Administration

  • Oral
  • Preparation of suspension (for 150 mL of a 2 mg/mL suspension)
  • Add 75 mL of Ora-Plus® oral suspending vehicle to an amber polyethylene terephthalate (PET) bottle containing fifteen Benazepril 20 mg tablets, and shake for at least 2 minutes. Allow the suspension to stand for a minimum of 1 hour. After the standing time, shake the suspension for a minimum of 1 additional minute. Add 75 mL of Ora-Sweet® oral syrup vehicle to the bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 30 days in the PET bottle with a child-resistant screw-cap closure. Shake the suspension before each use.

Monitoring

Geriatric Use

  • Benazepril and benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdose

  • Patients should be closely monitored for blood pressure and clinical symptoms. Supportive management should be employed to ensure adequate hydration and to maintain systemic blood pressure.

Renal Artery Stenosis

Use of Potassium Supplements and Potassium-Sparing Diuretics

Use of Lithium

Use of Anti-Diabetics

  • In rare cases, diabetic patients receiving an ACE inhibitor (including Benazepril) concomitantly with insulin or oral anti-diabetics may develop hypoglycemia. Such patients should therefore be advised about the possibility of hypoglycemic reactions and should be monitored accordingly.

Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

IV Compatibility

FDA Package Insert for Benazepril contains no information regarding IV Compatibility.

Overdosage

Acute Overdose

Signs and Symptoms

  • Human overdoses of Benazepril have not been reported, but the most common manifestation of human Benazepril overdosage is likely to be hypotension, which can be associated with electrolyte disturbances and renal failure.

Management

  • Laboratory determinations of serum levels of Benazepril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of Benazepril overdose.
  • No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of Benazepril and its metabolites. Benazepril is only slightly dialyzable, but dialysis might be considered in overdosed patients with severely impaired renal function (see Warnings).
  • Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of Benazepril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of Benazepril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat Benazepril overdose by infusion of normal saline solution.
  • Patients should be closely monitored for blood pressure and clinical symptoms. Supportive management should be employed to ensure adequate hydration and to maintain systemic blood pressure.
  • In the case of marked hypotension, physiological saline solution should be administered intravenously; depending on the clinical situation the use of vasopressors (e.g., catecholamines i.v.) may be considered.

Chronic Overdose

Signs and Symptoms

  • FDA Package Insert for Benazepril contains no information regarding Signs and Symptoms in Chronic Overdose.

Management

  • FDA Package Insert for Benazepril contains no information regarding Management in Chronic Overdose.

Pharmacology

Mechanism of Action

  • Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Hypertensive patients treated with Benazepril alone for up to 52 weeks had elevations of serum potassium of up to 0.2 mEq/L. Similar patients treated with Benazepril and hydrochlorothiazide for up to 24 weeks had no consistent changes in their serum potassium.
  • ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Benazepril remains to be elucidated.

Structure

Benazepril structure.png
Benazepril
Systematic (IUPAC) name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-
Identifiers
CAS number 86541-75-5
ATC code C09AA07
PubChem 5362124
DrugBank DB00542
Chemical data
Formula C24H28N2O5 
Mol. mass 424.49 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Protein binding 96.7%
Metabolism Hepatic glucuronidation
Half life 10-11 hours
Excretion Renal and biliary
Therapeutic considerations
Pregnancy cat.

D

Legal status

Prescription only

Routes Oral

  • Benazepril hydrochloride is a white to off-white crystalline powder, soluble (>100 mg/mL) in water, in ethanol, and in methanol. Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid monohydrochloride.
  • Its empirical formula is C24H28N2O5•HCl, and its molecular weight is 460.96.

Pharmacodynamics

  • Single and multiple doses of 10 mg or more of Benazepril cause inhibition of plasma ACE activity by at least 80%-90% for at least 24 hours after dosing. Pressor responses to exogenous angiotensin I were inhibited by 60%-90% (up to 4 hours post-dose) at the 10-mg dose.

Pharmacokinetics

  • Following oral administration of Benazepril, peak plasma concentrations of Benazepril are reached within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.
  • Cleavage of the ester group (primarily in the liver) converts Benazepril to its active metabolite, benazeprilat. Peak plasma concentrations of benazeprilat are reached 1-2 hours after drug intake in the fasting state and 2-4 hours after drug intake in the nonfasting state. The serum protein binding of Benazepril is about 96.7% and that of benazeprilat about 95.3%, as measured by equilibrium dialysis; on the basis of in vitro studies, the degree of protein binding should be unaffected by age, hepatic dysfunction, or concentration (over the concentration range of 0.24-23.6 µmol/L).
  • Benazepril is almost completely metabolized to benazeprilat, which has much greater ACE inhibitory activity than Benazepril, and to the glucuronide conjugates of Benazepril and benazeprilat. Only trace amounts of an administered dose of Benazepril can be recovered in the urine as unchanged Benazepril, while about 20% of the dose is excreted as benazeprilat, 4% as benazepril glucuronide, and 8% as benazeprilat glucuronide.
  • The kinetics of Benazepril are approximately dose-proportional within the dosage range of 10-80 mg.
  • In adults, the effective half-life of accumulation of benazeprilat following multiple dosing of benazepril hydrochloride is 10-11 hours. Thus, steady-state concentrations of benazeprilat should be reached after 2 or 3 doses of benazepril hydrochloride given once daily.
  • The kinetics did not change, and there was no significant accumulation during chronic administration (28 days) of once-daily doses between 5 mg and 20 mg. Accumulation ratios based on AUC and urinary recovery of benazeprilat were 1.19 and 1.27, respectively.
  • Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects. In patients with renal failure, biliary clearance may compensate to an extent for deficient renal clearance.
  • When dialysis was started 2 hours after ingestion of 10 mg of Benazepril, approximately 6% of benazeprilat was removed in 4 hours of dialysis. The parent compound, Benazepril, was not detected in the dialysate.
  • In pediatric patients, (N=45) hypertensive, age 6 to 16 years, given multiple daily doses of Benazepril (0.1 to 0.5 mg/kg), the clearance of benazeprilat for children 6 to 12 years old was 0.35 L/hr/kg, more than twice that of healthy adults receiving a single dose of 10 mg (0.13 L/hr/kg). In adolescents, it was 0.17 L/hr/kg, 27% higher than that of healthy adults. The terminal elimination half-life of benazeprilat in pediatric patients was around 5 hours, one-third that observed in adults.

Nonclinical Toxicology

  • FDA Package Insert for Benazepril contains no information regarding Nonclinical Toxicology.

Clinical Studies

Hypertension
Adult
  • In single-dose studies, Benazepril lowered blood pressure within 1 hour, with peak reductions achieved 2-4 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. In multiple-dose studies, once-daily doses of 20-80 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 6-12/4-7 mmHg. The trough values represent reductions of about 50% of that seen at peak.
  • Four dose-response studies using once-daily dosing were conducted in 470 mild-to-moderate hypertensive patients not using diuretics. The minimal effective once-daily dose of Benazepril was 10 mg; but further falls in blood pressure, especially at morning trough, were seen with higher doses in the studied dosing range (10-80 mg). In studies comparing the same daily dose of Benazepril given as a single morning dose or as a twice-daily dose, blood pressure reductions at the time of morning trough blood levels were greater with the divided regimen.
  • The antihypertensive effects of Benazepril were not appreciably different in patients receiving high- or low-sodium diets.
  • In normal human volunteers, single doses of Benazepril caused an increase in renal blood flow but had no effect on glomerular filtration rate.
Pediatric
  • In a clinical study of 107 pediatric patients, 7 to 16 years of age, with either systolic or diastolic pressure above the 95th percentile, patients were given 0.1 or 0.2 mg/kg then titrated up to 0.3 or 0.6 mg/kg with a maximum dose of 40 mg once daily. After four weeks of treatment, the 85 patients whose blood pressure was reduced on therapy were then randomized to either placebo or Benazepril and were followed up for an additional two weeks. At the end of two weeks, blood pressure (both systolic and diastolic) in children withdrawn to placebo rose by 4 to 6 mmHg more than in children on Benazepril. No dose-response was observed for the three doses.

How Supplied

  • Benazepril is available in tablets of 5 mg, 10 mg, 20 mg, and 40 mg, packaged with a desiccant in bottles of 100 tablets.
  • Each tablet is imprinted with Benazepril on one side and the tablet strength (“5,” “10,” “20,” or “40”) on the other.
  • National Drug Code (NDC):
Benazepril tablet how supplied.png
  • Storage
  • Do not store above 30°C (86°F). Protect from moisture. Dispense in tight container (USP).
  • Manufactured by
  • Novartis Pharmaceuticals Corporation, Suffern, New York 10901
  • Distributed by
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936

Images

Drug Images

Amlodipine Besylate and Benazepril Hydrochloride NDC 00937370.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7370
Dosage: 10 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937370

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 00937371.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7371
Dosage: 10 mg
Color(s): Orange, White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937371

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 00937372.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7372
Dosage: 20 mg
Color(s): Pink, White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937372

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 00937373.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7373
Dosage: 20 mg
Color(s): Blue
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937373

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 00937670.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7670;TEVA;7670
Dosage: 40 mg
Color(s): Blue
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937670

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 00937671.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: TEVA;7671;TEVA;7671
Dosage: 40 mg
Color(s): Blue
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00937671

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 05913761.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: AB;5
Dosage: 40 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:05913761

Drug Label Author: Watson Laboratories, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 05913762.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: AB;6
Dosage: 40 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:05913762

Drug Label Author: Watson Laboratories, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 07812271.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: S;SANDOZ;571
Dosage: 10 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:07812271

Drug Label Author: Sandoz Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 07812272.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: S;SANDOZ;572
Dosage: 10 mg
Color(s): Brown
Shape: Capsule
Size (mm): 19
Score: 1
NDC:07812272

Drug Label Author: Sandoz Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 07812273.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: S;SANDOZ;573
Dosage: 20 mg
Color(s): Pink
Shape: Capsule
Size (mm): 19
Score: 1
NDC:07812273

Drug Label Author: Sandoz Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 07812274.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: S;SANDOZ;574
Dosage: 20 mg
Color(s): Purple
Shape: Capsule
Size (mm): 19
Score: 1
NDC:07812274

Drug Label Author: Sandoz Inc

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 551110339.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: RDY;339
Dosage: 10 mg
Color(s): Grey, Yellow
Shape: Capsule
Size (mm): 19
Score: 1
NDC:551110339

Drug Label Author: Dr.Reddy's Laboratories Limited

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine Besylate and Benazepril Hydrochloride NDC 551110340.jpg

Drug Name: Amlodipine Besylate and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: RDY;340
Dosage: 20 mg
Color(s): Grey, Orange
Shape: Capsule
Size (mm): 19
Score: 1
NDC:551110340

Drug Label Author: Dr.Reddy's Laboratories Limited

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine and Benazepril Hydrochloride NDC 03786896.jpg

Drug Name: Amlodipine and Benazepril Hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: MYLAN;6896
Dosage: 10 mg
Color(s): Blue
Shape: Capsule
Size (mm): 21
Score: 1
NDC:03786896

Drug Label Author: Mylan Pharmaceuticals Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine besylate and benazepril hydrochloride NDC 05913759.jpg

Drug Name: Amlodipine besylate and benazepril hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: AB;3
Dosage: 20 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:05913759

Drug Label Author: Watson Laboratories, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Amlodipine besylate and benazepril hydrochloride NDC 05913760.jpg

Drug Name: Amlodipine besylate and benazepril hydrochloride
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: AB;4
Dosage: 20 mg
Color(s): White
Shape: Capsule
Size (mm): 19
Score: 1
NDC:05913760

Drug Label Author: Watson Laboratories, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 00935124.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 93;5124
Dosage: 5 mg
Color(s): Yellow
Shape:
Size (mm): 8
Score: 1
NDC:00935124

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 00935125.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 93;5125
Dosage: 10 mg
Color(s): Yellow
Shape:
Size (mm): 8
Score: 1
NDC:00935125

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 00935126.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 93;5126
Dosage: 20 mg
Color(s): Pink
Shape:
Size (mm): 8
Score: 1
NDC:00935126

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 00935127.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 93;5127
Dosage: 40 mg
Color(s): Pink
Shape:
Size (mm): 8
Score: 1
NDC:00935127

Drug Label Author: Teva Pharmaceuticals USA Inc

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 01850048.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: E;48
Dosage: 40 mg
Color(s): Red
Shape: Round
Size (mm): 8
Score: 1
NDC:01850048

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 01850053.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: E;53
Dosage: 10 mg
Color(s): Orange
Shape: Round
Size (mm): 8
Score: 1
NDC:01850053

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 01850505.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: E;5
Dosage: 5 mg
Color(s): Yellow
Shape: Round
Size (mm): 8
Score: 1
NDC:01850505

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 03780441.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: M;441
Dosage: 5 mg
Color(s): White
Shape: Round
Size (mm): 6
Score: 1
NDC:03780441

Drug Label Author: Mylan Pharmaceuticals Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 422910160.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 51;A
Dosage: 5 mg
Color(s): White
Shape: Round
Size (mm): 5
Score: 1
NDC:422910160

Drug Label Author: AvKARE, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 422910161.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 52;A
Dosage: 10 mg
Color(s): White
Shape: Round
Size (mm): 6
Score: 1
NDC:422910161

Drug Label Author: AvKARE, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 422910162.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 53;A
Dosage: 20 mg
Color(s): White
Shape: Round
Size (mm): 8
Score: 1
NDC:422910162

Drug Label Author: AvKARE, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 422910163.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 54;A
Dosage: 40 mg
Color(s): White
Shape: Round
Size (mm): 9
Score: 1
NDC:422910163

Drug Label Author: AvKARE, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 510790145.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: M;443
Dosage: 10 mg
Color(s): White
Shape: Round
Size (mm): 7
Score: 1
NDC:510790145

Drug Label Author: Mylan Institutional Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 581770344.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): Benazepril Hydrochloride[Benazepril]
Imprint: ETH;344
Dosage: 40 mg
Color(s): Blue
Shape: Round
Size (mm): 8
Score: 1
NDC:581770344

Drug Label Author: ETHEX

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 651620752.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 52;A
Dosage: 10 mg
Color(s): White
Shape: Round
Size (mm): 6
Score: 1
NDC:651620752

Drug Label Author: Amneal Pharmaceuticals

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 651620753.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 53;A
Dosage: 20 mg
Color(s): White
Shape: Round
Size (mm): 8
Score: 1
NDC:651620753

Drug Label Author: Amneal Pharmaceuticals

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride NDC 651620754.jpg

Drug Name: Benazepril hydrochloride
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: 54;A
Dosage: 40 mg
Color(s): White
Shape: Round
Size (mm): 9
Score: 1
NDC:651620754

Drug Label Author: Amneal Pharmaceuticals

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 01850124.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: E124
Dosage: 5 mg
Color(s): White
Shape: Oval
Size (mm): 13
Score: 2
NDC:01850124

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 01850204.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: E204
Dosage: 10 mg
Color(s): Pink
Shape: Oval
Size (mm): 13
Score: 2
NDC:01850204

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 01850211.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: E211
Dosage: 20 mg
Color(s): Purple
Shape: Oval
Size (mm): 13
Score: 2
NDC:01850211

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 01850277.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: E277
Dosage: 20 mg
Color(s): Red
Shape: Oval
Size (mm): 13
Score: 2
NDC:01850277

Drug Label Author: Eon Labs, Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 03784735.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: M;735
Dosage: 10 mg
Color(s): White
Shape: Round
Size (mm): 10
Score: 2
NDC:03784735

Drug Label Author: Mylan Pharmaceuticals Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 03784745.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: M;745
Dosage: 20 mg
Color(s): White
Shape: Oval
Size (mm): 16
Score: 2
NDC:03784745

Drug Label Author: Mylan Pharmaceuticals Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Benazepril Hydrochloride and Hydrochlorothiazide NDC 03784775.jpg

Drug Name: Benazepril Hydrochloride and Hydrochlorothiazide
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: M;775
Dosage: 20 mg
Color(s): White
Shape: Oval
Size (mm): 15
Score: 2
NDC:03784775

Drug Label Author: Mylan Pharmaceuticals Inc.

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin HCT NDC 00780452.jpg

Drug Name: Lotensin HCT
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: LOTENSIN;HCT;72;72
Dosage: 10 mg
Color(s): Pink
Shape: Oval
Size (mm): 12
Score: 2
NDC:00780452

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin HCT NDC 00780453.jpg

Drug Name: Lotensin HCT
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: LOTENSIN;HCT;74;74
Dosage: 20 mg
Color(s): Grey
Shape: Oval
Size (mm): 12
Score: 2
NDC:00780453

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin HCT NDC 00780454.jpg

Drug Name: Lotensin HCT
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT], HYDROCHLOROTHIAZIDE[HYDROCHLOROTHIAZIDE]
Imprint: LOTENSIN;HCT;75;75
Dosage: 20 mg
Color(s): Red
Shape: Oval
Size (mm): 12
Score: 2
NDC:00780454

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin NDC 00780447.jpg

Drug Name: Benazepril
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: LOTENSIN;5
Dosage: 5 mg
Color(s): Yellow
Shape: Round
Size (mm): 8
Score: 1
NDC:00780447

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin NDC 00780448.jpg

Drug Name: Benazepril
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: LOTENSIN;10
Dosage: 10 mg
Color(s): Yellow
Shape: Round
Size (mm): 8
Score: 1
NDC:00780448

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin NDC 00780449.jpg

Drug Name: Benazepril
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: LOTENSIN;20
Dosage: 20 mg
Color(s): Pink
Shape: Round
Size (mm): 8
Score: 1
NDC:00780449

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotensin NDC 00780450.jpg

Drug Name: Benazepril
Ingredient(s): BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: LOTENSIN;40
Dosage: 40 mg
Color(s): Red
Shape: Round
Size (mm): 8
Score: 1
NDC:00780450

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotrel NDC 00780379.jpg

Drug Name: Lotrel
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: Lotrel;0379
Dosage: 40 mg
Color(s): Blue
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00780379

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
Lotrel NDC 00780384.jpg

Drug Name: Lotrel
Ingredient(s): AMLODIPINE BESYLATE[AMLODIPINE], BENAZEPRIL HYDROCHLORIDE[BENAZEPRILAT]
Imprint: Lotrel;0384
Dosage: 40 mg
Color(s): Blue
Shape: Capsule
Size (mm): 19
Score: 1
NDC:00780384

Drug Label Author: Novartis Pharmaceuticals Corporation

This pill image is provided by the National Library of Medicine's PillBox.
... further results

Package and Label Display Panel

Lotensin tablet 5 mg package
Lotensin tablet 10 mg package
Lotensin tablet 20 mg package
Lotensin tablet 40 mg package
Lotensin tablet 5 mg Display Panel
Lotensin tablet 10 mg Display Panel
Lotensin tablet 20 mg Display Panel
Lotensin tablet 40 mg Display Panel

Patient Information

Patient Information from FDA

  • Pregnancy
  • Female patients of childbearing age should be told about the consequences of exposure to Benazepril during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.
  • Angioedema
  • Angioedema, including laryngeal edema, can occur at any time with treatment with ACE inhibitors. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.
  • Symptomatic Hypotension
  • Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Benazepril should be discontinued until the prescribing physician has been consulted.
  • Hyperkalemia
  • Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.
  • Neutropenia

Patient Information from NLM

For patient information about benazepril from NLM, click here.

Precautions with Alcohol

Alcohol-Benazepril interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Lotensin®

Look-Alike Drug Names

Benazepril — Benadryl®

Lotensin® — Latensin®, Lioresal®, Lovastatin

Drug Shortage Status

Price

References

  1. "LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]".
  2. Yancy, CW.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, DE.; Drazner, MH.; Fonarow, GC.; Geraci, SA.; Horwich, T. (2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 128 (16): e240–327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058. Unknown parameter |month= ignored (help)
  3. O'Gara, PT.; Kushner, FG.; Ascheim, DD.; Casey, DE.; Chung, MK.; de Lemos, JA.; Ettinger, SM.; Fang, JC.; Fesmire, FM. (2013). "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 127 (4): e362–425. doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Maschio, G.; Alberti, D.; Locatelli, F.; Mann, JF.; Motolese, M.; Ponticelli, C.; Ritz, E.; Janin, G.; Zucchelli, P. (1999). "Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group". J Cardiovasc Pharmacol. 33 Suppl 1: S16–20, discussion S41-3. PMID 10028949.
  5. 5.0 5.1 Maschio, G.; Alberti, D.; Janin, G.; Locatelli, F.; Mann, JF.; Motolese, M.; Ponticelli, C.; Ritz, E.; Zucchelli, P. (1996). "Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group". N Engl J Med. 334 (15): 939–45. doi:10.1056/NEJM199604113341502. PMID 8596594. Unknown parameter |month= ignored (help)
  6. Neutel, JM.; Smith, DH.; Weber, MA. (2004). "Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass". Am J Hypertens. 17 (1): 37–42. PMID 14700510. Unknown parameter |month= ignored (help)




































"Triangle" is not in the list (Round, Oval, Square, Triangular, Capsule, Pentagon, Hexagon, Diamond, Gear, DoubleCircle, ...) of allowed values for the "Pill Shape" property.
"Triangle" is not in the list (Round, Oval, Square, Triangular, Capsule, Pentagon, Hexagon, Diamond, Gear, DoubleCircle, ...) of allowed values for the "Pill Shape" property.
"Triangle" is not in the list (Round, Oval, Square, Triangular, Capsule, Pentagon, Hexagon, Diamond, Gear, DoubleCircle, ...) of allowed values for the "Pill Shape" property.
"Triangle" is not in the list (Round, Oval, Square, Triangular, Capsule, Pentagon, Hexagon, Diamond, Gear, DoubleCircle, ...) of allowed values for the "Pill Shape" property.

Linked-in.jpg